Ozdemir M, Ozdemir G, Zencirci B, Oksuz H
Department of Ophthalmology, Medical Faculty of Kahramanmaras Sutcu Imam University, T-46050 Kahramanmaras, Turkey.
Br J Anaesth. 2004 Feb;92(2):231-4. doi: 10.1093/bja/aeh043.
We compared the efficacy and safety of articaine 2% with a mixture of lidocaine 2% and bupivacaine 0.5% without hyaluronidase for peribulbar anaesthesia in cataract surgery.
In this double-blind randomized clinical study, 58 cataract patients were allocated to receive either articaine 2% with epinephrine 1:200 000 or a mixture of equal parts of lidocaine 2% with epinephrine 1.25:100 000 and bupivacaine 0.5%. Ocular and eyelid movement scores, the number of supplementary injections, total volume of solution used and pain and complications during injection and surgery were used as clinical end-points.
Articaine produced greater akinesia after 5 min (P=0.03). Eighteen patients (60%) in the articaine group and 26 (93%) in the lidocaine/bupivacaine group required a second injection (P=0.003). A third injection was needed by two patients (7%) in the articaine group and 12 (43%) in the lidocaine/bupivacaine group (P=0.001). The total mean volume of local anaesthetic required to achieve akinesia was mean 9.4 (SD 1.7) ml in the articaine group and 11.28 (1.86) ml in the lidocaine/bupivacaine group (P<0.001). Median pain score was lower in the articaine group than in lidocaine/bupivacaine group during injection (P=0.004) and surgery (P=0.014). There was no difference between the groups for the incidence of complications.
Articaine 2% without hyaluronidase is more advantageous than a mixture of lidocaine 2% and bupivacaine 0.5% without hyaluronidase for peribulbar anaesthesia in cataract surgery.
我们比较了2%阿替卡因与不含透明质酸酶的2%利多卡因和0.5%布比卡因混合物在白内障手术球周麻醉中的有效性和安全性。
在这项双盲随机临床研究中,58例白内障患者被分配接受2%阿替卡因加1:200 000肾上腺素或等量的2%利多卡因加1.25:100 000肾上腺素与0.5%布比卡因的混合物。眼部和眼睑运动评分、追加注射次数、所用溶液总量以及注射和手术期间的疼痛及并发症被用作临床终点。
阿替卡因在5分钟后产生了更强的运动不能(P = 0.03)。阿替卡因组18例患者(60%)和利多卡因/布比卡因组26例患者(93%)需要第二次注射(P = 0.003)。阿替卡因组2例患者(7%)和利多卡因/布比卡因组12例患者(43%)需要第三次注射(P = 0.001)。达到运动不能所需局部麻醉剂的总平均量在阿替卡因组为9.4(标准差1.7)ml,在利多卡因/布比卡因组为11.28(1.86)ml(P < 0.001)。注射期间(P = 0.004)和手术期间(P = 0.014)阿替卡因组的疼痛评分中位数低于利多卡因/布比卡因组。两组并发症发生率无差异。
不含透明质酸酶的2%阿替卡因在白内障手术球周麻醉中比不含透明质酸酶的2%利多卡因和0.5%布比卡因混合物更具优势。